Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Expected: Shareholders Back Bristol's $74bn Celgene Buy

Executive Summary

With no more activist investor challenge, shareholders of both companies overwhelmingly approved the deal. Bristol said it will have leading positions in oncology and cardiovascular disease, and gain five potential blockbusters in the Celgene buyout.

Advertisement

Related Content

Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets
Celgene/Bristol's Revlimid Patent Risk Incrementally Lower After PTAB Denies Alvogen IPR
Bristol Approached Celgene Nearly Two Years Ago, Got A Better Deal Later
Bristol/Celgene A Record-Setting Merger, If It Happens
CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market
Poseida, Legend/Janssen Look To Snag Celgene/Bluebird's BCMA Crown
'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS
Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety
More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125062

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel